Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003–2008)

Authors


Corresponding author: A, Xhaard, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Service Hématologie-greffe 1 avenue Claude Vellefaux, 75475 Paris, Cedex 10, France
E-mail: alienor.xhaard@sls.aphp.fr

Abstract

Clin Microbiol Infect 2012; 18: E396–E400

Abstract

We conducted a nationwide retrospective study to evaluate clinical characteristics and outcome of mucormycosis among allogeneic haematopoietic stem cell transplant recipients. Twenty-nine patients were diagnosed between 2003 and 2008. Mucormycosis occurred at a median of 225 days after allogeneic haematopoietic stem cell transplant, and as a breakthrough infection in 23 cases. Twenty-six patients were receiving steroids, mainly for graft-versus-host disease treatment, while ten had experienced a prior post-transplant invasive fungal infection. Twenty-six patients received an antifungal treatment; surgery was performed in 12. Overall survival was 34% at 3 months and 17% at 1 year.

Ancillary